EMA Recommends Upadacitinib for Rheumatoid Arthritis EMA Recommends Upadacitinib for Rheumatoid Arthritis
A European Medicines Agency advisory panel recommended marketing authorization for upadacitinib for the treatment of patients with rheumatoid arthritis.International Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
More News: Arthritis | Drugs & Pharmacology | European Medicines Agency (EMA) | Marketing | Rheumatoid Arthritis | Rheumatology